JTC PLC/ JE00BF4X3P53 /
| 2024-05-28 5:29:59 PM | Chg. +6.00 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 935.00GBX | +0.65% | 6,558 Turnover(GBP): 61,531.2900 |
-Bid Size: - | -Ask Size: - | 946.00 | 929.00 |
GlobeNewswire
2:05 PM
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire
05-23
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis ...
GlobeNewswire
05-22
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positi...
GlobeNewswire
05-21
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for t...
GlobeNewswire
05-21
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent...
GlobeNewswire
05-20
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important...
GlobeNewswire
05-16
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-15
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
05-14
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire
05-14
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GlobeNewswire
05-14
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
05-13
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference ...
GlobeNewswire
05-09
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
05-07
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Ru...
GlobeNewswire
05-02
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
GlobeNewswire
05-01
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex...
